Oncostatin-M receptor subunit beta (OSMR) (OSMR)

The Oncostatin-M receptor subunit beta (OSMR) is a member of the type I cytokine receptor family and a critical component of the interleukin-6 (IL-6) receptor subfamily (UniProt Q99650). It forms a functional heterodimeric complex with the glycoprotein 130 (gp130) subunit to mediate signaling for Oncostatin M (OSM), a pleiotropic cytokine involved in diverse biological processes including inflammation, cell proliferation, and tissue remodeling (PubMed: 10477551). Additionally, OSMR beta pairs with the IL-31 receptor A (IL31RA) to form the functional receptor for IL-31, a cytokine primarily associated with pruritus and skin inflammation (PubMed: 15184896). Dysregulation of OSMR signaling is implicated in various pathological conditions, including chronic inflammatory diseases like atopic dermatitis and prurigo nodularis, as well as certain cancers and fibrotic disorders (PubMed: 28671663). Therapeutic strategies targeting OSMR, such as the monoclonal antibody vixarelimab, aim to block the dual signaling of OSM and IL-31 to alleviate inflammation and itch (Kiniksa Pharmaceuticals). By inhibiting these pathways, such therapies provide a multi-pronged approach to treating complex inflammatory skin conditions where both OSM and IL-31 play significant roles.

Other names

OSMRBOSMR-betaInterleukin-31 receptor subunit beta-likePLCA1

Antagonist monoclonal antibody targeting the OSMR beta subunit to block signaling of Oncostatin M (via OSMR/gp130) and Interleukin-31 (via OSMR/IL31RA) (Kiniksa Pharmaceuticals).